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Methods. The clinical and epidemiological data of 702 patients with mild-to-moderate COVID-19 were col-
lected from 19 European Hospitals. The following data were extracted: age, sex, ethnicity, tobacco consumption,
comorbidities, general, and otolaryngological symptoms. Dysphonia and otolaryngological symptoms were self-
assessed through a 4-point scale. The prevalence of dysphonia, as part of the COVID-19 symptoms, was assessed.
The outcomes were compared between dysphonic and nondysphonic patients. The association between dyspho-
nia severity and outcomes was studied through Bayesian analysis.
Results. A total of 188 patients were dysphonic, accounting for 26.8% of cases. Females developed more fre-
quently dysphonia than males (P = 0.022). The proportion of smokers was significantly higher in the dysphonic
group (P = 0.042). The prevalence of the following symptoms was higher in dysphonic patients compared with
nondysphonic patients: cough, chest pain, sticky sputum, arthralgia, diarrhea, headache, fatigue, nausea, and
vomiting. The severity of dyspnea, dysphagia, ear pain, face pain, throat pain, and nasal obstruction was higher
in dysphonic group compared with nondysphonic group. There were significant associations between the severity
of dysphonia, dysphagia, and cough.
Conclusion. Dysphonia may be encountered in a quarter of patients with mild-to-moderate COVID-19 and
should be considered as a symptom list of the infection. Dysphonic COVID-19 patients are more symptomatic
than nondysphonic individuals. Future studies are needed to investigate the relevance of dysphonia in the
COVID-19 clinical presentation.
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Since the first reported cases from Wuhan, the coronavirus
disease 2019 (COVID-19) has spread rapidly worldwide.1
As of April 25, a total of 2,719,897 individuals have been
diagnosed through laboratory testing, with 187,705 corre-
sponding deaths.2 According to Asian studies, the clinical
presentation of COVID-19 mainly includes fever, fatigue,
cough, and anorexia.3,4 However, recent European epide-
miological studies suggested that European mild-to-mod-
erate COVID-19 patients could present a different clinical
picture than Asian.5 In Europe, the most prevalent symp-
toms are headache, total loss of smell, nasal obstruction
and cough.5,6 Thus, the otolaryngological symptoms are
more prevalent than previously presumed in Asia.
Throughout a recent epidemiological study,7 we observed
the occurrence of dysphonia in some COVID-19 patients,
with a minority reporting aphonia over the clinical course
of the disease.
The aim of this study was to investigate the occurrence of
dysphonia in mild-to-moderate COVID-19 patients.METHODS
Five European Ethics Committees approved the study pro-
tocol (HAP2020-011; CHUSP20032020; EpiCURA-2020-
2303, CHUC,P20/30-24/03-B325-2020; J.Bordet Institute:
CE3137). The patient informed consent was obtained elec-
tronically.Setting & patients
From March 22 to April 24, 2020, the data of hospitalized
or home-managed COVID-19 patients were collected by
otolaryngologists and nonotolaryngologist physicians from
19 European Hospitals (Paris, Marseille, Milan, Verona,
Naples, Genova, Florence, Foggia, Forli, Sevilla, Santiago
de Compostela, San Sebastian, Mons, Brussels, Charleroi,
and Saint-Ghislain).
The diagnosis of Covid-19 infection was based on the
WHO interim guidance.8 Precisely, nasal or throat swabs
were collected in suspected patients and the virus was
identified through reverse transcription polymerase chain
reaction (RT-PCR) analysis. The details of the viral
RNA extraction and analyses are available in a previous
paper.7
The mild-to-moderate COVID-19 patients were identi-
fied through different ways. First, the database of the lab-
oratories of the hospitals provided a list of hospitalized or
home-managed patients. Second, many patients were
referred by the family physician or specialists from hospi-
tal departments (eg, Emergency, Internal Medicine, or
Otolaryngology Departments). A public call of University
of Mons allowed an increase in the recruitment of
patients. Third, many infected health care workers were
included.
Patients who were hospitalized in intensive care units
were not included due to their health status and the inabil-
ity to answer to the questions. Patients who reporteddysphonia prior to the infection were not included in the
present analysis. Patients with a history of head & neck
trauma, (chemo) radiotherapy, benign or malignant laryn-
geal lesions, or head and neck cancer surgery were identi-
fied through the epidemiological questionnaire and
carefully excluded.
Regarding the inclusion and exclusion criteria, the
patients included in the present study were defined as mild-
to-moderate COVID-19 patients.Epidemiological & clinical outcomes
Due to the sanitary situation, the data were collected
through an electronic patient-reported outcome question-
naire. Home-managed patients were contacted over the
phone. Physicians completed the questionnaire in the
patient’s room for hospitalized patients through an elec-
tronic device. For these patients, physicians had access to
the patient medical records to complete some data. The
professional Survey Monkey (San Mateo, California,
USA) was used for the patient reported outcome ques-
tionnaire.
The following epidemiological and clinical data were con-
sidered: age, sex, ethnicity, tobacco consumption, comor-
bidities, general, and otolaryngological symptoms. The
general symptoms included headache, asthenia, myalgia,
arthralgia, cough, loss of appetite, dyspnea, fever, diarrhea,
nausea/vomiting, abdominal pain, and chest pain. The oto-
laryngological symptoms included nasal obstruction, rhi-
norrhea, postnasal drip, sore throat, face pain, dysphonia,
ear pain, dysphagia, and sticky throat mucus. Otolaryn-
gological symptoms were assessed through a 4-point scale,
ranging from 0 (=no symptom) to 4 (=very severe symp-
tom). The prevalence rates of total or partial loss of smell
and dysgeusia were evaluated through questions from the
smell and taste component of the National Health and
Nutrition Examination Survey (NHNES).8 NHNES is a
population survey that monitors the health of U.S. citizens
through a nationally representative sample of 5,000 persons
on a yearly basis.8Statistical methods
The statistical analysis was realized through Bayesian net-
works. The details about the qualitative and quantitative
models of the network analysis were reported in a previous
study.7 The outcomes were compared between dysphonic
and nondysphonic patients. The relationships between dys-
phonia, epidemiological data and general and otolaryn-
gological symptoms were studied. A P - value <0.05 was
considered as significant.RESULTS
The data of 702 patients were collected. Among them, 188
reported dysphonia (26.8%) as a COVID-19 symptom while
514 patients did not report dysphonia during the clinical
course of the disease. Seven dysphonic patients reported
TABLE 1.
Epidemiological Characteristics of Dysphonic and Nondysphonic Patients
Characteristic Patients Dysphonic Nondysphonic
(n = 702) (n = 188) (n = 514)
Age
Median (SD) - yo 40.3 § 11.8 42.0 § 11.9 39.6 § 11.7
Gender (n - %)
Male 206 (29.2) 44 (23.4) 162 (31.5)
Female 496 (70.8) 144 (76.6) 352 (68.5)
Ethnicity (n - %)
European 640 (91.2) 172 (91.5) 469 (91.2)
Asian 11 (1.6) 2 (1.1) 9 (1.8)
Black African 14 (2.0) 1 (0.5) 13 (2.5)
North African 26 (3.7) 10 (5.3) 16 (3.1)
North American 1 (0.1) 0 (0) 1 (0.2)
South American 5 (0.1) 2 (1.1) 3 (0.6)
Oceanian 0 (0) 0 (0) 0 (0)
Mixing 4 (0.6) 1 (0.5) 3 (0.6)
Addictions (n - %)
Nonsmoker 597 (85.0) 148 (78.2) 450 (87.5)
Mild smoker (1−10 cigarettes daily) 83 (11.8) 19 (10.1) 64 (12.5)
Moderate smoker (11−20 cigarettes daily) 18 (2.6) 9 (4.8) 9 (1.8)
Heavy smoker (>20 cigarettes daily) 4 (0.6) 2 (1.1) 2 (0.4)
Allergic patients 126 (17.9) 37 (19.7) 89 (17.3)
Comorbidities
Allergic rhinitis 75 (10.7) 23 (12.2) 52 (10.1)
High blood pressure 60 (8.5) 15 (8.0) 45 (8.8)
GERD 53 (7.5) 15 (8.0) 38 (7.4)
Asthma 42 (6.0) 13 (6.9) 29 (5.6)
Hypothyroidism (treated) 42 (6.0) 12 (6.4) 30 (5.8)
Depression 23 (3.3) 9 (4.8) 14 (2.7)
CRS with or without polyps 11 (1.6) 5 (2.7) 6 (1.2)
Heart problems 8 (1.1) 2 (1.1) 6 (1.2)
Diabetes (insulin-dependent) 8 (1.1) 4 (2.1) 4 (0.8)
Autoimmune diseases 3 (0.4) 1 (0.5) 2 (0.4)
Respiratory insufficiency 3 (0.4) 2 (1.1) 1 (0.2)
Hypothyroidism (untreated) 2 (0.3) 0 (0) 2 (0.4)
Renal failure 0 (0) 0 (0) 0 (0)
Hepatic insufficiency 0 (0) 0 (0) 0 (0)
Neurological diseases 0 (0) 0 (0) 0 (0)
The percentages are in brackets. Abbreviations: CRS, chronic rhinosinusitis; GERD, gastroesophageal reflux disease; SD, standard deviation.
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The characteristics of patient groups are described in
Table 1. There were 70.8% of females, the proportion of
females reaching 76.6% in the dysphonic group. The female
proportion was significantly higher in the dysphonic group
compared to the nondysphonic group (P = 0.022). The
majority of patients were Caucasian. The percentage of
smokers was significantly higher in dysphonic group com-
pared with nondysphonic group (P = 0.042). The propor-
tion of allergic patients was similar in both groups. The
most prevalent comorbidities were allergic rhinitis, hyper-
tension, and gastroesophageal reflux disease.
The prevalence of general symptoms in both groups is
available in Table 2. Patients with dysphonia had a higherproportion of systemic symptoms compared with nondy-
sphonic patients, including cough, chest pain, sticky spu-
tum, arthralgia, diarrhea, headache, fatigue, nausea, and
vomiting (Figure 1).
Symptoms are described in Table 3. According to
NHNES questions, the total and partial losses of smell con-
cerned 128 (68.1%) and 20 (10.6%) dysphonic patients,
respectively. In the group of nondysphonic patients, there
were 369 (71.8%) and 66 (12.8%) individuals with total and
partial losses of smell, respectively. As reported in Table 3,
dysphonic patients had higher proportions of dyspnea, dys-
phagia, ear pain, face pain, throat pain, and nasal obstruc-
tion compared with nondysphonic individuals. The severity
of dysphonia was significantly associated with the severity
TABLE 2.
Prevalence of General Symptoms in Dysphonic and Nondysphonic Patients
Symptoms Patients Dysphonic Nondysphonic
(n = 702) (n = 188) (n = 514)
Fever 287 (40.9) 89 (47.3) 198 (38.5)
Cough 351 (50.0) 119 (63.3) 232 (45.1)
Chest pain 179 (25.5) 64 (34.0) 115 (22.4)
Loss of appetite 263 (37.5) 92 (48.9) 171 (333)
Sticky Sputum 47 (6.7) 22 (11.7) 25 (4.9)
Arthralgia 181 (25.8) 71 (37.8) 110 (21.4)
Myalgia 371 (52.9) 108 (57.5) 263 (51.2)
Diarrhea 213 (30.3) 71 (37.8) 142 (27.6)
Abdominal pain 113 (16.1) 40 (21.3) 73 (14.2)
Nausea/vomiting 108 (15.4) 39 (20.7) 69 (13.4)
Headache 447 (63.7) 143 (76.1) 304 (59.1)
Asthenia 519 (73.9) 161 (85.6) 358 (69.6)
The percentages are in brackets.
FIGURE 1. The Proportions of general symptoms in dysphonic and nondysphonic patients.
The ordinate axis consists of the prevalence of symptoms (percentages). Dysphonic Patients are represented in orange, nondysphonic are in
green. Abbreviations: Abdo pain, Abdominal pain; LoA, loss of appetite; V, vomiting.
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4 Journal of Voice, Vol.&&, No.&&, 2020of dysphagia. A significant positive association was found
between dysphonia and cough.DISCUSSION
The spread of COVID-19 in Europe led to the emergence of
an otolaryngological clinical picture of the infection, whichis mainly associated with loss of smell and taste. However,
many other otolaryngological symptoms could be prevalent
in COVID-19. The self-reported dysphonia could concern a
quarter of COVID-19 patients.
Dysphonia is encountered in less than 20% of common
viral infections such as common cold or flu.9,10 Naturally,
the prevalence of dysphonia in COVID-19 remains lower
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Jerome R. Lechien, et al Coronavirus & Voice 5compared with other common symptoms, such as total loss
of smell and taste. However, the place of dysphonia in the
diagnosis of the disease and, regarding our results, as part
of a more severe clinical presentation of the disease have
to be investigated in future studies. The realization of
multidimensional investigation of voice in COVID-19 is
still challenging regarding the risk of contamination
related to the videolaryngostroboscopic examination.
Physicians have to keep in mind that COVID-19 patients
may develop dysphonia throughout the clinical course of
disease as in common viral infection of the upper aerodi-
gestive tract mucosa.
Dysphonia could be likely related to laryngeal involve-
ment by the airway inflammatory process and may be
caused by vocal fold edema or inflammation. However,
the etiology of dysphonia in COVID-19 patients needs to
be investigated. An ongoing study conducted in the Anat-
omy Department of University of Mons observed that
vocal folds were associated with a high expression of
angiotensin-converting enzyme 2 (ACE2), which is the
COVID-19 receptor (Figure 2) (No published data). These
preliminary data could strengthen the corditis etiology of
dysphonia related to COVID-19; ACE2 being present in
epithelia of the lung, small intestine, vascular endothe-
lium, and oral cavity.11,12 Studies about the expression of
ACE2 receptor by laryngeal cells would provide interest-
ing findings to clarify the pathogenesis of dysphonia in
patients affected by COVID-19. Moreover, regarding the
ACE2 expression in lung, abdominal, and chest muscles,13
it could be conceivable that muscle or lung virus-related
impairments may lead to dysphonia. As for the ACE2
expression in laryngeal tissue, this hypothesis has to be
investigated in future studies.
Another issue that could be studied concerns the impact
of gender in the voice-related presentation of COVID-19.
Indeed, female could be most at risk of dysphonia in
COVID-19, which could involve gender-related difference
in the inflammatory process.14 The future studies have to be
conducted in the context of potential hormonal and gender
differences in the expression of ACE2, in the inflammatory
process and, therefore, the clinical presentation of the
disease.7,15
This study is a preliminary epidemiological study investi-
gating potential association between COVID-19 and the
development of dysphonia. Many limitations have to be
addressed. First, the lack of video-laryngostroboscopical
examination of dysphonic patients limits us in the character-
ization of the dysphonia. Due to the sanitary situation, it is
however discouraged to perform such examinations in
COVID-19 patients. Second, many confounding factors
might have occurred such as the occurrence of co-infection
by COVID-19 and other virus (influenza), potentiating the
risk to develop inflammation in the upper aerodigestive tract
mucosa and dysphonia, the stress of patients and the stress-
related risk to develop laryngopharyngeal reflux, and the
occurrence of seasonal allergies with laryngopharyngeal
symptoms.
FIGURE 2. Angiotensin converting enzyme-2 (ACE2) expression in vocal folds.
The immunohistochemistry analysis found a high expression of ACE2 in vocal fold tissues of healthy human (ongoing study - unpublished
data). Ampliation: 1/100.
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Dysphonia was encountered in 26.8% of patients with mild-
to-moderate COVID-19 and could be added to the symp-
tom list of COVID-19. Dysphonia may appear in patientswith a more severe clinical COVID-19 presentation. Only
3.7% of patients reported severe dysphonia characterized by
aphonia. Future studies are needed to investigate the rele-
vance of dysphonia in the COVID-19 clinical presentation.
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